SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Clarification sought from Sun Pharma Advanced Research Company Ltd
The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on January 3, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the Company''s Code of Conduct for Prevention of Insider Trading, the Trading Window for trading in shares of the Company will be closed from January 1, 2024 till 48 hours after the declaration of Unaudited Financial Result of the Company for the quarter and nine months ended December 31, 2023 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
Transcript of Investor''s Call pertaining to the update on Clinical Programs and R&D Pipeline. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Statement Of Deviation In The Use Of Proceeds Of Preferential Issue
As per the letter attached SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Outcome Of The Board Meeting Held On November 06, 2023
Financial Results for the quarter and half year ended September 30, 2023 SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Audio Playback Of The Investor Presentation For Update On Clinical Programs And R&D Pipeline
Audio Recording of the Investor Call held on November 02, 2023 at 4.00 PM on the Clinical Programs and R&D Pipeline of the Company. SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Change in Management
Change in Senior Management of the Company SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
Update on Clinical Programs and pipeline SPARC inks agreement on hair loss drug with Johns Hopkins and Czech research institute
SCD-153 is a first-in-class topical drug for the treatment of alopecia areata (involving hair loss), developed jointly by SPARC, JHU and IOCB SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB